Trial ID or NCT#

NCT01120639

Status

NOT RECRUITING

Purpose

The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy with the FDA approved chemotherapy drug temozolomide

Official Title

A Phase I/II Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Scott G. Soltys, MD
Radiation oncologist
Assistant Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Steven D. Chang, MD
Neurosurgeon, Aneurysm neurosurgeon, Cerebrovascular neurosurgeon, Pituitary tumors neurosurgeon, Stereotactic neurosurgeon, Neuro-oncologist
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology-Head and Neck Surgery
Iris C. Gibbs, MD, FACR
Radiation oncologist, Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Lawrence Recht, MD
Neuro-oncologist
Professor of Neurology and, by courtesy, of Neurosurgery at the Stanford University Medical Center
Griffith Harsh, MD
Neurosurgeon
Professor of Neurosurgery and, by courtesy, of Otolaryngology-Head and Neck Surgery at the Stanford University Medical Center
Heather Wakelee, MD
Medical oncologist, Thoracic specialist
Professor of Medicine (Oncology) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Ccto-office@stanford.edu
(650) 498-7061